down
About Us
JC Medical, Inc. is a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases.
About the JC Medical J-Valve™ Transfemoral (TF) System
The J·Valve Transcatheter Aortic Valve Replacement (TAVR) system is a revolutionary next generation heart valve implantation system. The system is designed to replace a patient’s failed native aortic heart valve. The J·Valve TAVR System consists of a uniquely designed transcatheter aortic valve and delivery device designed by JC Medical in the USA. Other systems are indicated for aortic stenosis alone and aortic bioprostheses are often difficult to position accurately. The J·Valve system was designed to address these problems in order to create a more useful and reliable replacement transcatheter aortic valve for surgeons and patients.
This system can be used to treat:
- Pure aortic regurgitation
- A combination of aortic stenosis and regurgitation, also known as
“mixed disease”
Other features of the system:
- System is easy to learn and simple to operate
- Automatic anatomic alignment with the native aortic root
J-Valve TF System
This system has not yet been approved by the FDA and is currently not for sale.
J-Valve TF
Bioprosthesis
The J·Valve Transcatheter Aortic Valve
positions itself according to the anatomy
of the native aortic annulus. It naturally
slides into place, allowing doctors to
rely on tactile feedback to achieve
optimal positioning.
Key Design Features:
- U-shaped “anchor rings” facilitate accurate self-positioning of the replacement aortic valve
- Low profile design minimizes risk of coronary blockage
- With five different valve sizes, the system ensures a perfect fit for each patient
J-Valve TF
Delivery Device
Doctors can perform transcatheter replacement
aortic valve implantations accurately because
the intuitive design of the delivery device is
easy to use.
Key Design Features:
- Valve loads seamlessly into the nosecone
- Locking mechanism ensures valve deployment at the correct time
- Two control knobs release the valve into place
JC Medical News
Genesis MedTech Completes Enrollment in its United States Early Feasibility Study Utilizing the J-Valve™ Transfemoral System for Patients with Severe Aortic Regurgitation
February 5, 2024 – Read the Article
Genesis MedTech initiates enrolment in its North American Early Feasibility Study using the J-Valve™ Transfemoral System for patients with severe aortic regurgitation
October 23, 2023 – Read the Article
Genesis MedTech announces FDA Breakthrough Device designation for the J-Valve™ Transfemoral System
August 1, 2023 – Read the Article
Genesis Medtech Names Inaugural President to Drive Commercial Strategy for North America
May 15th, 2023 – Read the Article
Genesis MedTech Acquires JC Medical, Creates New Structural Heart Franchise
Feb 4th, 2022 – Read the Article
Cardiology Today’s Intervention (Healio) – First US patient implanted with novel TAVR valve
January 7th, 2019 – Read the Article
Medical Device and Diagnostic Industry (MD+DI) – First World-Wide Patient Treated – JC Medical Becoming Serious Challenger in TAVR Fray
May 31st, 2018 – Read the Article
First Patient in the U.S. Treated with the J-Valve TF System
May 4th, 2019 – Watch video
HonorHealth performs first non-surgical heart valve replacement in AZ
November 16, 2023 – Watch video
Clinical Data
Transapical transcatheter aortic valve implantation using a new TAVI system for high-risk patients with severe aortic stenosis. Heart, Lung and Circulation – 2017Treatment of pure aortic regurgitation using a second-generation transcatheter aortic valve implantation system. The Journal of the American College of Cardiology (JACC) – 2016
Presentations: